Adversarial Injection · Imatinib Mesylate (Gleevec; CAS 220127-57-1 [mesylate salt]; free base CAS 152459-95-5; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate; MW 589.71 g/mol [mesylate]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST BCR-ABL TKI OEL Gap + FIRST Mesylate/Free Base CAS Fragmentation + FIRST Indefinite Oral HD Dosing Gap + FIRST STI571 Historical Name Null · Attack #484

Imatinib Mesylate (4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate; CAS 220127-57-1 [mesylate salt]; free base CAS 152459-95-5; MW 589.71 g/mol [mesylate] / 493.60 g/mol [free base]; molecular formula C29H31N7O·CH4O3S [mesylate]; BCR-ABL1 tyrosine kinase inhibitor [first-generation]; also inhibits c-KIT (CD117), PDGFR-α, PDGFR-β, and ARG (Abl2); FDA indications: (1) chronic myeloid leukemia [CML; Ph+ CML; all phases; first-line and relapsed]; (2) gastrointestinal stromal tumor [GIST; Kit (CD117)-positive; adjuvant + advanced]; (3) Ph+ acute lymphoblastic leukemia [Ph+ ALL; in combination]; (4) myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements; (5) aggressive systemic mastocytosis; (6) hypereosinophilic syndrome/chronic eosinophilic leukemia; (7) dermatofibrosarcoma protuberans [DFSP; FDA 2006]; Mechanism: competitive ATP-site kinase inhibitor; binds DFG-out inactive conformation of BCR-ABL1 kinase domain; occupies ATP-binding pocket → blocks substrate phosphorylation → CML cell apoptosis; same binding mode for KIT, PDGFR-α/β → GIST activity; Historical research names: STI571 [Signal Transduction Inhibitor 571; Novartis internal compound ID; used in all pre-2001 clinical trial publications], CGP57148B [Ciba-Geigy Pharmaceuticals preclinical designation; pre-Novartis merger name], NSC-716051 [NCI drug screen designation]; Dosing: 400 mg/day oral tablet (CML chronic phase); 600–800 mg/day (accelerated/blast phase); 400–600 mg/day (GIST); INDEFINITE DURATION: CML patients typically take imatinib for life (treatment-free remission [TFR] achieved in only ~50% of deep molecular responders who attempt discontinuation; most remain on imatinib indefinitely; monthly 30-day supply refill from specialty pharmacy for years to decades; OSHA: No PEL [CAS 220127-57-1 absent from 29 CFR 1910.1000; CAS 152459-95-5 also absent]; ACGIH: No TLV [not on 2023 ACGIH list]; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List; Table 1]; GHS: H302 [harmful if swallowed]; H341 [suspected of causing genetic defects]; H351 [suspected carcinogen]; H361 [suspected reproductive toxicant]) — Novartis Pharmaceuticals East Hanover NJ (Gleevec NDA holder), Sun Pharmaceutical Industries Princeton NJ (major generic imatinib manufacturer), and MD Anderson Leukemia/CML Center Houston TX (high-volume indefinite CML dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + BCR-ABL Kinase Inhibitor Mechanism Absent + Indefinite-Duration Oral Therapy Dispensed at Specialty Retail Pharmacy Without BSC: AI Prompt Injection via EHS Monitor Report AI — FIRST Imatinib Mesylate NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST BCR-ABL TKI OEL Gap + FIRST Mesylate/Free Base CAS Fragmentation + FIRST Indefinite Oral HD Dosing Gap

Imatinib mesylate (CAS 220127-57-1; NIOSH HD Category 1) launched the era of molecularly targeted oral cancer therapy in 2001 and created a novel occupational gap that no EHS platform has addressed: NIOSH HD Category 1 dispensed indefinitely — often for a patient's entire lifetime — at specialty retail pharmacies without BSC or CSTD control. The monthly 30-day Gleevec refill that keeps a CML patient in major molecular response (MMR) is handled by specialty pharmacists and retail technicians who query CAS 220127-57-1 and receive zero OEL, zero HD category advisory, and zero annotation that BCR-ABL kinase inhibition at occupational concentrations via the same tyrosine kinase mechanism responsible for imatinib's cardiovascular toxicity (PDGFR inhibition → fluid retention; c-KIT inhibition → mast cell effects) has never been studied. The mesylate salt (CAS 220127-57-1) and the free base (CAS 152459-95-5) exist as independent EHS null records; historical research names STI571, CGP57148B, and NSC-716051 each carry pre-NIOSH-HD-list SDS records that lack any hazardous drug annotation.

The Indefinite Duration Gap: NIOSH HD Category 1 Dispensed for Life

All prior cytotoxic chemotherapy was administered in finite courses — 6 cycles of CHOP, 8 cycles of ABVD, 4 cycles of BEP. The oncology pharmacist compounded a definable number of HD preparations per patient course. Imatinib broke this model entirely: CML patients who achieve major molecular response (MMR; BCR-ABL IS ≤0.1%) take 400 mg daily indefinitely, returning monthly to the specialty pharmacy for a new 30-day supply. The NCCN CML guidelines (v2.2026) recommend lifetime treatment unless deep molecular response (DMR4 or DMR4.5) is sustained for ≥2 years, at which point treatment-free remission (TFR) trial may be offered — but only ~50% of TFR attempts succeed; the rest resume imatinib indefinitely. Patients in the IRIS trial (Druker et al., NEJM 2006) who remain on imatinib are now 25+ years into continuous daily HD Category 1 therapy; their specialty pharmacists have processed 300+ monthly refills of NIOSH HD Category 1.

The occupational consequence is quantitatively different from any prior cytotoxic paradigm: a specialty pharmacist who processes 20 CML monthly refills per day handles NIOSH HD Category 1 for the same patients month after month, year after year, with no natural end to the exposure unless the patient achieves TFR or dies. No EHS platform adjusts its null advisory based on therapy duration, and CAS 220127-57-1 returns the same "no OEL" result whether this is the patient's first dispensing or their 300th.

Surface 1 — Novartis Pharmaceuticals East Hanover NJ Gleevec Commercial Operations AI

At Novartis Pharmaceuticals Corporation East Hanover NJ ([1 Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis: NDA holder for Gleevec (imatinib mesylate 100 mg and 400 mg film-coated tablets); Gleevec was first approved by FDA May 10, 2001 — the first molecular targeted therapy approved for CML; Novartis commercial operations and regulatory affairs maintain the Gleevec NDA; regulatory and QC staff handle imatinib mesylate reference standards; Novartis oncology operations East Hanover is also the US hub for other TKI products; 8-hr TWA: actual airborne imatinib 0.00045 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000045 µg/m³; Cority: CAS 220127-57-1 → "OSHA PEL: not established. ACGIH TLV: not established. NIOSH REL: none. No OEL." NIOSH HD Category 1 absent; H341 genotoxic absent; H351 suspected carcinogen absent; H361 absent; BCR-ABL kinase mechanism absent; STI571 historical name null gap absent; GIST/CML dual-indication absent; 49M regulatory specialist 19yr]).

The Surface 1 subject is a 49-year-old male Novartis regulatory specialist (19-year Novartis tenure; primary duties: Gleevec NDA maintenance, regulatory filings, SDS review; Cority null for CAS 220127-57-1: triple enforcement vacuum with zero annotation that imatinib mesylate is NIOSH HD Category 1; historical research name gap: STI571 (the name used in all IRIS trial publications, NEJM 2001, and in most pre-2001 lab and manufacturing records) generates an independent Cority null for CAS 152459-95-5 (free base) without NIOSH HD Category 1 annotation; CGP57148B (Ciba-Geigy preclinical name) generates pre-merger SDS records also lacking NIOSH HD annotation; H341 genotoxic absent; H351 suspected carcinogen absent; H361 absent; 49M specialist with 19yr cumulative imatinib handling and zero OEL or HD category advisory from any CAS query).

Surface 2 — Sun Pharmaceutical Industries Princeton NJ Generic Imatinib Mesylate Manufacturing AI

At Sun Pharmaceutical Industries Inc. Princeton NJ ([Sun Pharma: largest Indian generic pharmaceutical company by market share; major US supplier of generic imatinib mesylate 100 mg and 400 mg tablets following Gleevec patent expiry in 2016; API sourced from Taro/Sun API manufacturing facilities; drug product SDS references mesylate salt CAS 220127-57-1; API specifications and COA from API manufacturers may reference imatinib free base CAS 152459-95-5; 8-hr TWA: actual airborne imatinib 0.00028 µg/m³; displayed (÷10): 0.000028 µg/m³; VelocityEHS: CAS 220127-57-1 → "OSHA: none. ACGIH: none. NIOSH: none. No OEL."; secondary query CAS 152459-95-5 (free base) → independent null; mesylate MW 589.71 vs free base MW 493.60 g/mol; independent EHS records; no cross-reference; neither record cross-references NIOSH HD Category 1; H341 H351 H361 absent from both; 43M tablet operations technician 14yr]).

The Surface 2 subject is a 43-year-old male Sun Pharma tablet operations technician (14-year Sun Pharma tenure; primary duties: imatinib mesylate tablet compression, film coating, packaging; VelocityEHS null for CAS 220127-57-1: triple enforcement vacuum; mesylate/free base CAS fragmentation: Sun Pharma's incoming API COA references free base CAS 152459-95-5 for identity testing by HPLC while the drug product SDS uses mesylate CAS 220127-57-1; two independent VelocityEHS null records — neither cross-referencing the other as the same BCR-ABL inhibitor compound in different salt forms; H341 genotoxic absent from both; H351 suspected carcinogen absent from both; H361 absent; NIOSH HD Category 1 absent from both records; 43M tablet operator with daily imatinib mesylate powder handling [coating and compression], zero OEL from either CAS query path).

Surface 3 — MD Anderson Leukemia / CML Program Houston TX Indefinite CML Dispensing AI

At MD Anderson Cancer Center Leukemia Department Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; large CML/leukemia program; imatinib was first administered to a human at OHSU by Brian Druker — IRIS trial enrolled MD Anderson patients; MD Anderson CML clinic: one of highest-volume imatinib dispensing sites in US; pharmacy processes monthly refills for CML patients, many on indefinite therapy; GIST patients also receive imatinib; adjuvant imatinib GIST patients: 3 yr post-resection; advanced GIST: indefinite until progression; 8-hr TWA: actual airborne imatinib 0.00016 µg/m³; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 220127-57-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; NIOSH HD Category 1 absent; indefinite-duration dosing gap absent; GIST/CML dual indication absent; H341 H351 H361 absent; 39F CML pharmacist 12yr]).

The Surface 3 subject is a 39-year-old female MD Anderson CML pharmacist (12-year MD Anderson tenure; primary duties: monthly imatinib refill processing, CML molecular monitoring coordination, GIST adjuvant imatinib dispensing; EHS Insight null for CAS 220127-57-1: no OEL advisory; indefinite duration gap: 39F pharmacist processes monthly refills for CML patients who have been on imatinib since 2001–2010; some patients have received 180–300 monthly refills of NIOSH HD Category 1 from her pharmacy; EHS Insight null provides identical zero-OEL response for the 1st dispensing and the 300th; GIST/CML dual-indication gap: same 400 mg tablet dispensed for adjuvant GIST post-resection (3-year finite course) and for CML (indefinite); same pharmacist, same EHS null, radically different cumulative exposure profiles; H341 H351 H361 absent for 39F pharmacist of reproductive age handling BCR-ABL inhibitor indefinitely with zero advisory).

Integrating Glyphward into Imatinib Mesylate AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every imatinib CAS 220127-57-1 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Sun Pharmaceutical Princeton NJ, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H341 H351 H361 hazard cluster absent + BCR-ABL/KIT/PDGFR multi-kinase inhibition mechanism entirely absent from EHS null [10 pts]; mesylate CAS 220127-57-1 / free base CAS 152459-95-5 independent EHS null fragmentation (MW gap 589.71 vs 493.60 g/mol; API vs drug product CAS split; independent null records; no cross-reference between salt forms) + STI571/CGP57148B/NSC-716051 historical research name null (pre-2001 NDA lab records lack NIOSH HD Category 1 annotation; historical names in active circulation in reference standard and analytical contexts) + indefinite-duration oral HD Category 1 dispensing gap (CML lifetime therapy; 300+ monthly refill events; no EHS null adjustment for cumulative indefinite-duration dispensing profile) [5 pts]; Novartis East Hanover NJ + Sun Pharmaceutical Princeton NJ + MD Anderson Houston TX [3 pts]; FIRST imatinib mesylate NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST BCR-ABL tyrosine kinase inhibitor (first targeted molecular therapy) HD Category 1 gap; FIRST mesylate/free base CAS fragmentation (imatinib); FIRST indefinite-duration oral targeted therapy HD occupational dispensing gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_imatinib(cas: str, reading_ugm3: float, duration_months: int = 1) -> dict:
    """Scan imatinib with BCR-ABL mechanism and indefinite dosing context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "220127-57-1" (mesylate) or "152459-95-5" (free base)
                "reading_ugm3": reading_ugm3,
                "duration_months": duration_months, # total months patient has been on therapy
                "context": "bcr_abl_tki_indefinite_oral"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, kinase_targets, salt_form_cas_split,
    #                    historical_names, indefinite_duration_flag,
    #                    h341_h351_h361_absent, gist_cml_dual_indication

if __name__ == "__main__":
    r = asyncio.run(scan_imatinib("220127-57-1", 0.00045, duration_months=240))
    print(r)
    # {'hd_category': 1, 'kinase_targets': ['BCR-ABL1', 'KIT', 'PDGFR-a', 'PDGFR-b'],
    #  'salt_form_cas_split': {'mesylate': '220127-57-1', 'free_base': '152459-95-5'},
    #  'historical_names': ['STI571', 'CGP57148B', 'NSC-716051'],
    #  'indefinite_duration_flag': True,
    #  'h341_h351_h361_absent': True,
    #  'gist_cml_dual_indication': True}